



## Magenta Therapeutics Expands Leadership Team, Appoints Kristen Stants as Chief People Officer and Li Malmberg as Senior Vice President, Head of Manufacturing

February 5, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 5, 2020-- [Magenta Therapeutics](#) (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the expansion of its senior leadership with two new strategic hires, Kristen Stants as Chief People Officer and Li Malmberg, Ph.D., as Senior Vice President, Head of Manufacturing.

"As Magenta continues to grow and make significant strides across our pipeline, our people and our manufacturing are more vital than ever to advance our vision to deliver curative immune reset to all patients who can benefit," said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. "We welcome Kristen and Li's invaluable leadership and deep expertise in building out these essential areas of focus for Magenta."

Ms. Stants is a seasoned human resources professional and she joins Magenta from Alexion Pharmaceuticals, where she served as Head of Talent Strategy, responsible for organizational development and talent acquisition to expand the company's therapeutic pipeline. Prior to that, she led talent management and development strategy at Patheon Pharmaceuticals, in addition to 10 years at Biogen, where she held various leadership roles in executive development and organizational effectiveness. Ms. Stants holds a Master of Industrial and Labor Relations with a concentration in Organizational Behavior from Cornell University and a Bachelor of Science in Psychology and Business from the University of Oregon.

Dr. Malmberg is an accomplished technical leader with more than 25 years of manufacturing experience, coming to Magenta from Celgene Corporation, where she served as Vice President, Head of Biologics Development and Manufacturing, responsible for the company's manufacturing development and biologics manufacturing organization and advanced more than 20 biologics molecule and launched one commercial product. Prior to this role, Dr. Malmberg was Director, Head of Process Sciences at Abbvie, Inc. where she built and led an organization of more than 80 scientists and engineers responsible for biologics drug development from preclinical to commercial launch. Previous roles include various leadership roles in R&D at Abbott Laboratories. She holds a Ph.D. in Chemical Engineering from the University of Minnesota-Twin Cities; a Master of Science in Chemical Engineering from the University of Wisconsin-Madison; and a Bachelor of Science in Chemical Engineering from the University of Illinois at Urbana-Champaign.

### About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit [www.magentatx.com](http://www.magentatx.com).

Follow Magenta on Twitter: @magentatx.

### Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption "Risk Factors" in Magenta's Registration Statement on Form S-1, as updated by Magenta's most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200205005391/en/>

Source: Magenta Therapeutics

### Magenta Therapeutics:

Manisha Pai, Vice President, Communications & Investor Relations  
617-510-9193

[mpai@magentatx.com](mailto:mpai@magentatx.com)